237 related articles for article (PubMed ID: 17256055)
1. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.
Mo L; Zheng X; Huang HY; Shapiro E; Lepor H; Cordon-Cardo C; Sun TT; Wu XR
J Clin Invest; 2007 Feb; 117(2):314-25. PubMed ID: 17256055
[TBL] [Abstract][Full Text] [Related]
2. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.
Gao J; Huang HY; Pak J; Cheng J; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Oncogene; 2004 Jan; 23(3):687-96. PubMed ID: 14737103
[TBL] [Abstract][Full Text] [Related]
3. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior.
Garcia-España A; Salazar E; Sun TT; Wu XR; Pellicer A
Cancer Res; 2005 Feb; 65(4):1150-7. PubMed ID: 15734997
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.
Cheng J; Huang H; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Cancer Res; 2002 Jul; 62(14):4157-63. PubMed ID: 12124355
[TBL] [Abstract][Full Text] [Related]
6. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.
Zhou H; Huang HY; Shapiro E; Lepor H; Huang WC; Mohammadi M; Mohr I; Tang MS; Huang C; Wu XR
Carcinogenesis; 2012 Apr; 33(4):770-80. PubMed ID: 22287562
[TBL] [Abstract][Full Text] [Related]
7. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
8. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
9. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.
Tsuruta H; Kishimoto H; Sasaki T; Horie Y; Natsui M; Shibata Y; Hamada K; Yajima N; Kawahara K; Sasaki M; Tsuchiya N; Enomoto K; Mak TW; Nakano T; Habuchi T; Suzuki A
Cancer Res; 2006 Sep; 66(17):8389-96. PubMed ID: 16951148
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.
Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA
Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133
[TBL] [Abstract][Full Text] [Related]
11. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways.
Wang Z; Banerjee S; Ahmad A; Li Y; Azmi AS; Gunn JR; Kong D; Bao B; Ali S; Gao J; Mohammad RM; Miele L; Korc M; Sarkar FH
PLoS One; 2011; 6(6):e20537. PubMed ID: 21673986
[TBL] [Abstract][Full Text] [Related]
12. Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell.
Yeh HH; Giri R; Chang TY; Chou CY; Su WC; Liu HS
DNA Cell Biol; 2009 Mar; 28(3):131-9. PubMed ID: 19182994
[TBL] [Abstract][Full Text] [Related]
13. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
14. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.
Liu Z; Yokoyama NN; Blair CA; Li X; Avizonis D; Wu XR; Uchio E; Youssef R; McClelland M; Pollak M; Zi X
Mol Cancer Ther; 2016 Mar; 15(3):430-8. PubMed ID: 26921394
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
[TBL] [Abstract][Full Text] [Related]
16. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.
Vanbrocklin MW; Robinson JP; Lastwika KJ; McKinney AJ; Gach HM; Holmen SL
Neuro Oncol; 2012 Jan; 14(1):34-42. PubMed ID: 22015595
[TBL] [Abstract][Full Text] [Related]
17. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
Shin J; Yang J; Lee JC; Baek KH
Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency.
Leder A; McMenamin J; Zhou F; Moran JL; Beier DR; Leder P
Oncogene; 2008 Apr; 27(17):2456-65. PubMed ID: 17952114
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages.
Randle DH; Zindy F; Sherr CJ; Roussel MF
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9654-9. PubMed ID: 11481442
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras.
Young NP; Jacks T
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10184-9. PubMed ID: 20479239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
